Wellington Management focuses on investment management by applying its full resources to meet the needs of institutional clients they serve.
Business Model:
Revenue: $1B
Employees: 501-1,000
Address: 280 Congress Street
City: Boston
State: MA
Zip: 02210
Country: US
Wellington Management focuses on investment management. The company applies its full resources to meet the needs of the institutional clients they serve. Their investment approaches span the global equity, fixed income, currency, commodity, and alternatives markets. They also offer asset allocation, multi-manager, and specialty approaches. It was founded in 1928 and headquartered in Boston, Massachusetts.
Contact Phone:
+16179515000
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
4/2015 | Sharecare | Venture Round | 0 |
4/2000 | Optical Switch | Venture Round | 0 |
4/2015 | Voyager Therapeutics | Series B | 0 |
11/2018 | Auris Health | Series E | 0 |
4/2015 | Oscar Health | Series C | 145M |
6/2020 | Verve Therapeutics | Series A | 63M |
12/2018 | Swiggy | Series H | 1B |
7/2017 | Vets First Choice | Private Equity Round | 223M |
6/2022 | FalconX | Series D | 0 |
7/2017 | WeWork China | Series A | 0 |
10/2020 | Lordstown Motors | Post-IPO Equity | 500M |
2/2014 | nCino | Series B | 11M |
8/2018 | Slack | Series H | 427M |
12/2021 | JUSPAY | Series C | 60M |
4/2015 | Jounce Therapeutics | Series B | 0 |
1/2022 | Creditas | Series F | 0 |
12/2019 | Impulse Dynamics | Series D | 0 |
4/2014 | Pure Storage | Series F | 225M |
6/2017 | Nightstar Therapeutics | Series C | 45M |
1/2022 | CodeSee | Seed | 7M |
10/2014 | Fintiv | Series B | 185M |
3/2015 | Zuora | Series F | 0 |
11/2021 | Faire | Series G | 0 |
6/2021 | Payoneer | PIPE | 300M |
7/2020 | Olema Oncology | Series B | 54M |
3/2021 | Zenas BioPharma | Series A | - |
8/2017 | Atreca | Series B | 35M |
6/2021 | Perella Weinberg Partners | Post-IPO Equity | 125M |
4/2014 | Apigee | Venture Round | 0 |
6/2022 | Kinside | Series A | 0 |
8/2021 | Trove | Series D | 77.5M |
10/2020 | LianBio | Series A | 0 |
1/2021 | Verve Therapeutics | Series B | 94M |
2/2015 | Invuity | Equity | 22.9M |
9/2018 | Atreca | Series C | 125M |
10/2009 | neoSaej | Venture Round | 1.7M |
8/2016 | Compass | Series D | 75M |
3/2020 | Nurix Therapeutics | Private Equity Round | 120M |
2/2021 | Gemini Therapeutics | Post-IPO Equity | 0 |
11/2017 | HeartFlow | Series E | 0 |
6/2020 | Freeline | Series C | 80M |
3/2022 | Span.IO | Series B | 0 |
1/2017 | Neon Therapeutics | Series B | 70M |
12/2019 | Black Diamond Therapeutics | Series C | 0 |
12/2022 | Dataiku | Series F | 200M |
12/2020 | Edgewise Therapeutics | Series C | 95M |
4/2023 | HeartFlow | Series F | 0 |
6/2017 | Houzz | Series E | 400M |
3/2023 | CARGO Therapeutics | Series A | 0 |
11/2014 | Powa | Series C | 80M |
5/2021 | NiKang Therapeutics | Series C | 200M |
7/2022 | Meati Foods | Series C | 0 |
6/2021 | Lendbuzz | Series C | 0 |
9/2020 | Novellus | Series C | 57M |
8/2020 | PMV Pharmaceuticals | Series D | 70M |
3/2020 | JUSPAY | Series B | 21.6M |
5/2014 | Datalogix | Series C | 45M |
3/2021 | Scribe Therapeutics | Series B | 100M |
6/2015 | Cogent Biosciences | Series B | 65M |
6/2019 | Omada Health | Series D | 73M |
4/2021 | Urban Company | Series F | 188M |
9/2016 | DEFY Media | Series B | 70M |
4/2019 | Prove (formerly Payfone) | Series G | 15.1M |
3/2021 | Paidy | Series D | 0 |
4/2021 | Swiggy | Series J | 0 |
11/2017 | Tricida | Series D | 0 |
4/2015 | Rethink Robotics | Series D | 13.4M |
2/2016 | Magic Leap | Series C | 793.5M |
1/2021 | Affinivax | Series C | 226M |
11/2021 | Chroma Medicine | Series A | 125M |
9/2022 | RayzeBio | Series D | 160M |
1/2015 | Global Blood Therapeutics | Series B | 48M |
9/2020 | Affirm | Series G | 500M |
4/2021 | Current | Series D | 220M |
9/2014 | Adaptimmune | Series A | 0 |
9/2020 | ESCAPE Bio | Venture Round | 73M |
8/2015 | Payoneer | Series E | 50M |
7/2021 | Blackbuck | Series E | 0 |
10/2021 | BetterUp | Series E | 0 |
9/2021 | Ventyx Biosciences | Series B | 0 |
8/2014 | The Honest Company | Series C | 70M |
5/2017 | Peloton | Series E | 0 |
9/2021 | SpotOn | Series E | 300M |
5/2015 | MarkLogic | Series F | 102M |
3/2021 | Entrada Therapeutics | Series B | 0 |
3/2015 | Birst | Series F | 65M |
7/2000 | SensAble Technologies | Series C | 23M |
10/2020 | Gracell Biotechnologies | Series C | 0 |
9/2021 | Asher Bio | Series B | 0 |
8/2020 | Synthego | Series D | 100M |
12/2020 | Cityblock Health | Series C | 160M |
4/2019 | Satsuma Pharmaceuticals | Series B | 0 |
10/2019 | Current | Series B | 31.2M |
9/2020 | Attentive | Series D | 230M |
1/2015 | Moderna Therapeutics | Series E | 0 |
6/2018 | ezCater | Series D | 100M |
5/2023 | Quince | Series B | 0 |
11/2022 | AMP Robotics | Series C | 0 |
12/2021 | ROKT | Series E | 325M |
1/2020 | Generation Bio | Series C | 110M |
4/2021 | Patreon | Series F | 155M |
3/2021 | Cityblock Health | Series C | 192M |
8/2014 | Pure Storage | Secondary Market | 60M |
1/2022 | Dave | Post-IPO Equity | 0 |
12/2014 | Redfin | Series G | 71M |
9/2020 | Skillz | Post-IPO Equity | 0 |
11/2022 | MBX Biosciences | Series B | 115M |
2/2022 | Synthego | Series E | 0 |
4/2015 | Warby Parker | Series D | 100M |
2/2021 | Nuvation Bio | Post-IPO Equity | 502M |
6/2020 | Goldfinch Biopharma | Series B | 100M |
9/2020 | Patreon | Series E | 90M |
9/2015 | General Assembly | Series D | 70M |
12/2022 | Apogee Therapeutics | Series B | 0 |
7/2021 | Markforged | Post-IPO Equity | 0 |
3/2023 | Span.IO | Series B | 0 |
4/2021 | Greenlight | Series D | 260M |
10/2018 | Coinbase | Series E | 300M |
10/2014 | Invitae | Series F | 0 |
9/2015 | Rubicon | Series C | 57.1M |
6/2015 | Airbnb | Series E | 1.5B |
6/2015 | Harry&s;s | Series C | 97.5M |
2/2021 | Butterfly Network | Post-IPO Equity | 175M |
4/2019 | ezCater | Series D | 150M |
4/2019 | Affirm | Series F | 300M |
6/2021 | Latch | Post-IPO Equity | 190M |
2/2021 | Artiva Biotherapeutics | Series B | 120M |
4/2023 | Clerkie | Series A | 0 |
8/2014 | Civitas Therapeutics | Series C | 0 |
11/2014 | Nivalis Therapeutics | Venture Round | 30M |
11/2021 | Acrivon Therapeutics | Series B | 0 |
6/2021 | Faire | Series F | 260M |
10/2020 | Scopely | Series E | 340M |
5/2015 | DocuSign | Series F | 0 |
6/2015 | TabbedOut | Series C | 21.5M |
8/2015 | Rhythm Metabolic | Series A | 40M |
11/2022 | Zenas BioPharma | Series B | 0 |
6/2023 | Upstream Bio | Series B | 0 |
3/2020 | Kymera Therapeutics | Series C | 102M |
6/2014 | Uber | Series D | 1.4B |
9/2021 | Arcadia | Series D | 0 |
12/2021 | Anchorage Digital | Series D | 0 |
8/2014 | Lookout | Series F | 150M |
1/2015 | SoFi | Series D | 213M |
11/2017 | Compass | Series E | 0 |
5/2021 | Snapdocs | Series D | 150M |
11/2019 | ACV | Series E | 150M |
9/2020 | Fore Biotherapeutics | Series C | 57M |
3/2021 | Ventyx Biosciences | Series A | 0 |
1/2021 | Design Therapeutics | Series B | 125M |
6/2016 | Mersana Therapeutics | Series C | 33M |
2/2021 | Centessa Pharmaceuticals | Series A | 250M |
7/2020 | VelosBio | Series B | 137M |
1/2020 | Aligos Therapeutics | Series B | 125M |
2/2022 | Somatus | Series E | 0 |
5/2021 | Nuvalent | Series B | 0 |
7/2021 | Strata Oncology | Series C | 0 |
6/2015 | CytomX Therapeutics | Series D | 70M |
6/2022 | Guild Education | Series F | 0 |
10/2017 | Forty Seven | Series B | 75M |
2/2017 | Fuze, an 8x8 company | Series E | 104M |
9/2018 | PagerDuty | Series D | 90M |
6/2020 | Prove (formerly Payfone) | Series H | 98M |
8/2018 | Peloton | Series F | 0 |
3/2015 | Nanigans | Series B | 24M |
1/2021 | Scorpion Therapeutics | Series B | 162M |
11/2014 | Blueprint Medicines | Series C | 50M |
4/2021 | Boundless Bio | Series B | 105M |
5/2023 | Boundless Bio | Series C | 0 |
3/2023 | Chroma Medicine | Series B | 0 |
2/2020 | Swiggy | Series I | 113M |
3/2016 | The Trade Desk | Series C | 60M |
6/2023 | Caraway | Series A | 0 |
5/2016 | Speakaboos | Series B | 12.5M |
5/2022 | Arcadia | Series E | 0 |
2/2015 | nCino | Series B | 29M |
9/2015 | SoFi | Series E | 1B |
10/2017 | PolicyBazaar | Series E | 77M |
1/2016 | ForeScout Technologies | Series G | 80M |
9/2021 | Archaea Energy | Post-IPO Equity | 0 |
8/2020 | Dyne Therapeutics | Series B | 115M |
8/2013 | Powa | Series A | 76M |
1/2022 | Digit Insurance | Venture Round | 70M |
1/2021 | Billtrust | Post-IPO Equity | 200M |
12/2014 | Coupang | Private Equity Round | 300M |
4/2014 | New Relic | Private Equity Round | 100M |
7/2022 | Moving Analytics | Series A | 0 |
7/2021 | Hyzon Motors | Post-IPO Equity | 0 |
3/2021 | Arrival | Post-IPO Equity | 400M |
4/2021 | Greenlight | Series D | 260M |
12/2020 | Creditas | Series E | 255M |
5/2019 | Away | Series D | 100M |
6/2021 | ironSource | Post-IPO Equity | 0 |
8/2014 | Nutanix | Series E | 140M |
7/2016 | Sprinklr | Series F | 105M |
12/2020 | Porch Group | Post-IPO Equity | 150M |
10/2020 | Olema Oncology | Series C | 85M |
4/2016 | Kala Pharmaceuticals | Series C | 68M |
10/2014 | WeWork | Series D | 355M |
5/2015 | Series G | 186M | |
10/2014 | GreenSky | Private Equity Round | 350M |
11/2020 | Current | Series C | 131M |
4/2021 | Scale AI | Series E | 325M |
7/2021 | Thriveworks | Venture Round | - |
12/2022 | ROKT | Secondary Market | - |
12/2017 | Neon Therapeutics | Series B | 36M |
8/2022 | SeatGeek | Series E | 238M |
9/2014 | Veracode | Series F | 40M |
2/2022 | Omada Health | Series E | 0 |
10/2018 | Tanium | Private Equity Round | 200M |
1/2021 | PPRO | Private Equity Round | 180M |
12/2019 | FORMA Therapeutics | Series D | 100M |
8/2015 | The Honest Company | Series D | 100M |
5/2021 | Oxford Nanopore Technologies | Venture Round | 270.8M |
7/2021 | Sundae | Series C | 0 |
3/2015 | Dataminr | Series D | 130M |
5/2016 | BEGiN | Series B | 0 |
11/2017 | Arcus Biosciences | Series C | 107M |
12/2021 | Course Hero | Series C | 380M |
7/2021 | Lucid Motors | Post-IPO Equity | 0 |
7/2021 | EVgo | Post-IPO Equity | 400M |
12/2015 | Allena Pharmaceuticals | Series C | 0 |
8/2015 | Klarna | Secondary Market | 80M |
5/2014 | Malauzai Software | Series C | 6.5M |
12/2021 | Olist | Series E | 186M |
10/2022 | immatics biotechnologies | Post-IPO Equity | 0 |
5/2014 | Spark Therapeutics | Series B | 72.8M |
9/2022 | flavrs | Seed Round | 0 |
7/2022 | Meati Foods | Series C | 0 |
7/2022 | Moving Analytics | Series A | 0 |
6/2022 | FalconX | Series D | 0 |
6/2022 | Kinside | Series A | 0 |
6/2022 | Guild Education | Series F | 0 |
5/2022 | Arcadia | Series E | 0 |
3/2022 | Span.IO | Series B | 0 |
2/2022 | Omada Health | Series E | 0 |
2/2022 | Somatus | Series E | 0 |
2/2022 | Synthego | Series E | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|